- Home
- NEOV vs MDWD Comparison
NEOV vs MDWD Comparison
Compare NEOV & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- MDWD
- Stock Information
- Founded
- NEOV 2018
- MDWD 2000
- Country
- NEOV United States
- MDWD Israel
- Employees
- NEOV N/A
- MDWD N/A
- Industry
- NEOV Industrial Machinery/Components
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- NEOV Miscellaneous
- MDWD Health Care
- Exchange
- NEOV Nasdaq
- MDWD Nasdaq
- Market Cap
- NEOV 181.8M
- MDWD 184.8M
- IPO Year
- NEOV N/A
- MDWD 2014
- Fundamental
- Price
- NEOV $4.17
- MDWD $17.64
- Analyst Decision
- NEOV Strong Buy
- MDWD Strong Buy
- Analyst Count
- NEOV 1
- MDWD 1
- Target Price
- NEOV $7.50
- MDWD $25.00
- AVG Volume (30 Days)
- NEOV 303.3K
- MDWD 68.1K
- Earning Date
- NEOV 02-07-2025
- MDWD 11-26-2024
- Dividend Yield
- NEOV N/A
- MDWD N/A
- EPS Growth
- NEOV N/A
- MDWD N/A
- EPS
- NEOV N/A
- MDWD N/A
- Revenue
- NEOV $2,471,178.00
- MDWD $19,720,000.00
- Revenue This Year
- NEOV $85.10
- MDWD $10.37
- Revenue Next Year
- NEOV $281.25
- MDWD $26.36
- P/E Ratio
- NEOV N/A
- MDWD N/A
- Revenue Growth
- NEOV N/A
- MDWD N/A
- 52 Week Low
- NEOV $0.63
- MDWD $11.04
- 52 Week High
- NEOV $6.11
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- NEOV 41.27
- MDWD 49.76
- Support Level
- NEOV $3.98
- MDWD $15.80
- Resistance Level
- NEOV $4.91
- MDWD $19.60
- Average True Range (ATR)
- NEOV 0.48
- MDWD 0.98
- MACD
- NEOV -0.11
- MDWD 0.06
- Stochastic Oscillator
- NEOV 10.22
- MDWD 48.42
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.